Oxytocin Modulates Eye Gaze Behavior During Social Processing

NCT ID: NCT03293511

Last Updated: 2018-10-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-09

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of the study is to examine whether the effects of intranasal oxytocin on eye-gaze behavior towards social stimuli are modulated via individual differences in trait autism

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this double-blind, within subject, placebo controlled design a total of n = 40 healthy male subjects will receive either 24 IU of oxytocin or placebo (interval between administration \> two weeks). 45 minutes after treatment subjects will undergo a total of 7 eye-tracking paradigms examining eye-gaze behavior during social processing: (1) dynamic social-nonsocial visual preference task during which movies of dynamic geometric images (DGI) and dynamic social images (DSI) will be presented; (2) non-biological versus biological motion task; (3) social attention and motivation of sharing enjoyment; (4) preference for emotional faces versus schematic faces (emoticons); (5) shared social attention - shared gaze direction with an actor shifting his attention to different objects; (6) preferred visual scanning of face regions in emotional faces; and, (7) eye gaze in response to empathy eliciting visual stimuli. Autistic and associated traits will be assessed using the Autism Spectrum Quotient (ASQ), Social Responsibilities Scale (SRS) and the Interpersonal Reactivity Index (IRI). Within-subject differences in the effects of oxytocin on social eye gazing behaviour will be related to individual differences in autistic traits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized placebo-controlled double-blind within-subject design
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Order of administration: oxytocin - placebo

Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray

Group Type EXPERIMENTAL

intranasal oxytocin

Intervention Type DRUG

24 IU of oxytocin nasal spray will be applied to each subject.

intranasal placebo

Intervention Type DRUG

24 IU of of placebo nasal spray will be applied to each subject.

Order of administration: placebo - oxytocin

Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).

Group Type EXPERIMENTAL

intranasal oxytocin

Intervention Type DRUG

24 IU of oxytocin nasal spray will be applied to each subject.

intranasal placebo

Intervention Type DRUG

24 IU of of placebo nasal spray will be applied to each subject.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intranasal oxytocin

24 IU of oxytocin nasal spray will be applied to each subject.

Intervention Type DRUG

intranasal placebo

24 IU of of placebo nasal spray will be applied to each subject.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects without any past or present psychiatric or neurological disorders

Exclusion Criteria

* History of brain injury
* Visual impairments
* Use of medication
* Contraindications for oxytocin administration
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Electronic Science and Technology of China

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Keith Kendrick

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Juan Kou, MSc

Role: STUDY_CHAIR

University of Electronic Science and Technology of China

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

school of life science and technology, University of Electronic Science and Technology of China

Chengdu, Sichuan, China

Site Status RECRUITING

University of Electronic Science and Technology of China

Chengdu, Sichuan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Keith M Kendrick, PhD

Role: CONTACT

86-28-61830811

Benjamin Becker, PhD

Role: CONTACT

86-28-61830988

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Juan Kou, Master

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Le J, Kou J, Zhao W, Fu M, Zhang Y, Becker B, Kendrick KM. Oxytocin Facilitation of Emotional Empathy Is Associated With Increased Eye Gaze Toward the Faces of Individuals in Emotional Contexts. Front Neurosci. 2020 Aug 11;14:803. doi: 10.3389/fnins.2020.00803. eCollection 2020.

Reference Type DERIVED
PMID: 32848571 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UESCT_neuSCAN_42

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intranasal Oxytocin in Youth With Autism
NCT05934812 NOT_YET_RECRUITING PHASE2
Autism Oxytocin Brain Project
NCT03033784 COMPLETED PHASE2
Oxytocin in Spectrum Autism Disorders
NCT03183674 COMPLETED PHASE1
Brain Dynamics of Oxytocin
NCT01834261 COMPLETED PHASE1